Form 4: Telesis Bio Inc. Executive Daniel Glenn Gibson Reports Stock Transactions

Chief Technology Officer Daniel Glenn Gibson of Telesis Bio Inc. reports acquisition of restricted stock units and stock options, as well as shares withheld for tax obligations.

Summary

• On June 22, 2023, Daniel Glenn Gibson, Chief Technology Officer of Telesis Bio Inc., was granted 6,400 restricted stock units (RSUs), each representing a contingent right to receive one share of the company's common stock.
• Vesting of these RSUs occurs in four equal installments of 25% on March 1st of 2024, 2025, 2026, and 2027, contingent upon continued service.
• Also on June 22, 2023, Gibson was granted an option to purchase 51,500 shares of common stock at an exercise price of $1.66.
• 25% of these options vested on March 1, 2024, with the remaining options vesting monthly thereafter over 36 months.
• On March 1, 2024, 656 shares were withheld by Telesis Bio Inc. to cover tax obligations related to the vesting of RSUs, at a price of $0.528 per share.
• Following these transactions, Gibson directly owns 105,562 shares of Telesis Bio Inc. common stock and holds options for 51,500 shares.

Sentiment

Score: 6

Explanation: The document is neutral in tone, simply reporting transactions. The grants are a positive sign of incentivizing management, but the tax withholding is a neutral event.

Positives

• The granting of RSUs and stock options to the Chief Technology Officer aligns his interests with the long-term success of the company.
• The vesting schedules for the RSUs and stock options incentivize continued service and contribution to the company's growth.

Negatives

• The withholding of shares to cover tax obligations reduces the executive's overall holdings, although this is a standard practice.

Risks

• The value of the RSUs and stock options is dependent on the future performance of Telesis Bio Inc.'s stock.
• If the stock price does not appreciate, the value of the options may be limited.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules suggest an expectation of continued employment and company performance.

Industry Context

This filing is a routine disclosure of insider transactions, which is common for publicly traded companies. It provides transparency into the actions of company executives regarding their holdings of company stock.

Comparison to Industry Standards

• Stock option and RSU grants are standard compensation practices in the biotechnology industry to attract and retain talent.
• Vesting schedules are typical, aligning executive compensation with long-term company performance, similar to companies like Amgen or Regeneron.
• The specific amounts and vesting terms would need to be compared to peer companies of similar size and stage to determine if they are in line with industry norms.

Stakeholder Impact

• Shareholders may view the grants as a positive sign of aligning management interests with company performance.
• Employees may see the grants as a standard part of executive compensation.

Key Dates

Keywords

Telesis Bio Inc., Daniel Glenn Gibson, stock options, restricted stock units, RSUs, Form 4, TBIO, insider trading